The therapeutic era of peptides began in 1921 with the discovery of insulin, a breakthrough that revolutionized diabetes and helped establish biologic therapies in medicine 1 Since then, peptide hormones like oxytocin and human growth hormone (GH) have entered clinical use, and glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide are now widely prescribed for obesity and metabolic diseaseconditions increasingly recognized for their effect on orthopaedic outcomes
The group argued that the changes would reduce regulatory uncertainty, prevent unintended consequences that affect product availability, and help sponsors plan better
Is this product easy to digest
Other motility agents like aloe and senna may also be helpful temporarily
In general, these substances tend to have mild, infrequent side effects
Danish Medical Society, Study of the Liver